NCT06111274 - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 29, 2026

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG

Pimicotinib (ABSK021)

The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.

Trial Locations (5)

Unknown

RECRUITING

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Harbin Medical University Cancer Hospital, Ha’erbin

RECRUITING

Shanghai East Hospital Tongji University, Shanghai

RECRUITING

Union Hospital Tongji Medical College Huazhong University of science and technolog, Wuhan